Skip Navigation


JAC Advance Access originally published online on November 5, 2004
Journal of Antimicrobial Chemotherapy 2004 54(6):1072-1077; doi:10.1093/jac/dkh475
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/6/1072    most recent
dkh475v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Hoban, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Hoban, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.54 no.6 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved

Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations

George G. Zhanel1,2,3,*, Christel Johanson1, Tamiko Hisanaga1, Chris Mendoza1, Nancy Laing1, Ayman Noreddin1, Aleksandra Wierzbowski1 and Daryl J. Hoban1,2

1Department of Medical Microbiology, Faculty of Medicine, University of Manitoba; Departments of 2 Clinical Microbiology and 3 Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada

* Correspondence address. Microbiology, Health Sciences Centre, MS673 – 820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9, Canada. Tel: +1-204-787-4902; Fax: +1-204-787-4699; Email: ggzhanel{at}pcs.mb.ca

Background: The association between macrolide resistance mechanisms and ketolide bacteriological eradication of Streptococcus pneumoniae remains poorly studied. The present study, using an in vitro model, assessed telithromycin pharmacodynamic activity against macrolide-susceptible and macrolide-resistant S. pneumoniae simulating clinically achievable free serum and epithelial lining fluid (ELF) concentrations.

Materials and methods: Two macrolide-susceptible [PCR-negative for both mef(A) and erm(B)] and six macrolide-resistant [five mef(A)-positive/erm(B)-negative displaying various degrees of macrolide resistance and one mef(A)-negative/erm(B)-positive] S. pneumoniae were tested. Telithromycin was modelled simulating a dosage of 800 mg by mouth once daily [free serum: maximum concentration (Cmax) 0.7 mg/L, t1/2 10 h; and free ELF: Cmax 6.0 mg/L, t1/2 10 h]. Starting inocula were 1 x 106 cfu/mL in Mueller–Hinton broth with 2% lysed horse blood. Sampling at 0, 2, 4, 6, 12, 24 and 48 h assessed the extent of bacterial killing (decrease in log10 cfu/mL versus initial inoculum).

Results: Telithromycin free serum concentrations achieved in the model were: Cmax 0.9±0.08 mg/L, AUC0–24 6.4±1.5 mg·h/L and t1/2 of 10.6±1.6 h. Telithromycin free ELF concentrations achieved in the model were: Cmax 6.6±0.8 mg/L, AUC0–24 45.5±5.5 mg·h/L and t1/2 of 10.5±1.7 h. At 2 h, free serum telithromycin concentrations achieved a 1.0–1.9 log10 reduction in inoculum compared with a 3.0–3.3 log10 reduction with free ELF versus macrolide-susceptible and macrolide-resistant S. pneumoniae. Free telithromycin serum and ELF concentrations simulating Cmax/MIC ≥14.1 and area under the curve to MIC (AUC0–24/MIC) ≥100 [time above the MIC (t > MIC) of 100%], were bactericidal (≥3 log10 killing) at 4, 6, 12, 24 and 48 h versus macrolide-susceptible and macrolide-resistant S. pneumoniae.

Conclusion: Telithromycin serum and ELF concentrations rapidly eradicated macrolide-susceptible and macrolide-resistant S. pneumoniae regardless of resistance phenotype. Achieving Cmax/MIC ≥14.1 and AUC0–24/MIC ≥100 resulted in bactericidal activity at 4 h with no regrowth over 48 h.

Keywords: S. pneumoniae , mef(A) , erm(B) , respiratory tract infections , ketolides


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
A. K. Wierzbowski, J. A. Karlowsky, D. J. Hoban, and G. G. Zhanel
In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS)
J. Antimicrob. Chemother., March 1, 2009; 63(3): 620 - 622.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.